Olistico Wealth LLC Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Olistico Wealth LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 141 shares of the biopharmaceutical company’s stock after selling 19 shares during the quarter. Olistico Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. Fairfield Financial Advisors LTD purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $37,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth about $49,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on REGN shares. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Bank of America reissued an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Oppenheimer dropped their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Evercore ISI decreased their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.1 %

REGN stock opened at $680.03 on Thursday. The company has a market capitalization of $74.73 billion, a PE ratio of 16.83, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company’s 50 day moving average price is $733.06 and its two-hundred day moving average price is $943.95.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.